About Assertio
Assertio is a company based in Lake Forest (United States) founded in 1995 was acquired by Zydus Life in May 2026. The company has 58 employees. Assertio has completed 2 acquisitions, including OTREXUP and Spectrum Pharmaceuticals. Assertio offers products and services including Pharmaceutical Products and Business Development Services. Assertio operates in a competitive market with competitors including Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
- Headquarter Lake Forest, United States
- Employees 58
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website assertiotx.com
- Social LinkedIn
- Acquired by Zydus Life (May 2026)
- Legal Name Assertio Therapeutics, Inc
- Annual Revenue$124.96 M (USD)-17.83as on Dec 31, 2024
- Net Profit-$21.58 M (USD)93.5as on Dec 31, 2024
- EBITDA$8.96 M (USD)-83.15as on Dec 31, 2024
- Latest Funding Round$575M (USD), Debt – Conventional
Mar 2015
- InvestorsZydus Life
& 11 more
- Employee Count58
- Investments & AcquisitionsOTREXUP
& 1 more
- Acquired by
Products & Services of Assertio
Assertio offers a comprehensive portfolio of products and services, including Pharmaceutical Products and Business Development Services.
Products for patient treatment and adverse event reporting
Services for partnerships and investor engagement
Funding Insights of Assertio
- Total Rounds 5
- Last Round Debt – Conventional — $575M
- First Round $7.5M
(Feb 1998)
- Investors Count 11
All 5 funding rounds of Assertio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2015 | $575M | Debt – Conventional | – | – | |
| Sep 2014 | $300M | Post-IPO | – | – | – |
| Jun 2008 | $3.8M | Debt – Conventional | – | – | |
| Apr 2003 | $20M | Post-IPO | – | – | |
| Feb 1998 | $7.5M | Post-IPO | – | – | – |
12 investors in total: 12 institutional.
Investors in Assertio
Assertio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Zydus Life, Oxford Finance and HBM Healthcare Investments.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Lumira Ventures is engaged in life sciences venture capital investment. | – | lumiraventures.com | Toronto, Canada | |
- | – | eastoncapital.com | - | |
Special situations in Europe are targeted for private equity investment. | – | ssvp.gg | Saint Peter Port, Guernsey | |
- | – | mdscapital.com | - | |
Life sciences focused VC firm funding companies in the US and Europe | 2001 | hbmhealthcare.com | Zug, Switzerland | |
Offers flexible financing and risk-sharing for healthcare industry assets globally. | 2015 | gehcfinance.com | Boston, United States | |
- | – | hqcm.com | - | |
R&D company focused on manufacturing of drugs for multiple therapeutic areas | 1983 | biovail.com | Mississauga, Canada |
Investor details for Assertio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Assertio
14 people are tracked at Assertio (6 in leadership, 8 in team); the tracked headcount is 58.
| Name | Role | Group |
|---|---|---|
Ajay Patel | Chief Financial Officer | Leadership |
James (Eddie) Owens | Regional Business Director-Mid Atlantic | Leadership |
Julie Henning | Vice President, Finance | Leadership |
Bill Iskos | Sr. Vice President of Operations | Leadership |
Jill Ngo, MBA | Director, Gross to Net | Leadership |
Dorothy Honda | Director Of Quality Assurance | Leadership |
Kessea Paulson | Inside Sales Specialist | Team |
John Lucas | Senior Specialty Sales Representative | Team |
John Bruce | Lead Accountant | Team |
Karen Cosby | Neurology Sales Specialist | Team |
Ryan Langner | Senior Manager, Operations | Team |
Tara Walters | Territory Manager | Team |
Nidhi Patel | QA Manager | Team |
Brian Schabdach | Senior Quality Assurance Manager | Team |
Complete people profiles for Assertio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Assertio
Assertio is a publicly listed company on the NASDAQ with ticker symbol ASRT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Dec 1997
- Listed onNASDAQ: DEPO
- Listed entityAssertio Holdings, Inc.
- Exchange sectorHealth technology
Investments & Acquisitions by Assertio
Assertio has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include OTREXUP and Spectrum Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Small molecule therapeutics for oncology and hematology are developed. | sppirx.com | Henderson, United States | 1987 | Apr 2023 | •••• | |
Methotrexate injections are offered via the official Otrexup website. | otrexup.com | Ewing Township, United States | 2012 | Dec 2021 | •••• |
Complete acquisition details for Assertio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Assertio
7 dated milestones of Assertio across 31 years, from founding to its latest funding, stage changes and deals.
- Founded Assertio is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $7.5M.
- Funding Latest funding round, Debt – Conventional, of $575.0M.
- Acquisition Acquires OTREXUP.
- Acquisition Acquires Spectrum Pharmaceuticals.
- Exit Acquired by Zydus Life.
Competitors of Assertio
Assertio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Cara Therapeutics, Eliem Therapeutics, Ethypharm and Zogenix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. | |
| ethypharm.com | 1977 | Saint Cloud, France | $248.09M | – | Therapies for pain and addiction treatment are developed. | |
| zogenix.com | 2006 | Emeryville, United States | $149.06M | 159 | Drug delivery systems for CNS disorders and pain are developed. | |
| painreform.com | 2007 | Herzliya, Israel | $12M | – | Pain treatment products are developed through reformulation technologies. | |
| herontx.com | 1983 | Redwood, United States | $32.14M | 21 | Reformulated injectables for chemotherapy side effects and pain are developed. | |
| trevena.com | 2007 | Philadelphia, United States | $203M | 35 | GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | |
| satsumarx.com | 2016 | San Francisco, United States | $74.13M | 24 | Therapeutics for migraine treatment are developed using nasal delivery. | |
| concentricanalgesics.com | 2014 | San Francisco, United States | $85.46M | – | Developer of platform for developing pro-drugs |
Detailed competitors of Assertio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Assertio
The website of Assertio (assertiotx.com) receives about 2.7K visits a month and ranks #6,727,386 among all websites worldwide, #6,728 in Biotechnology and Pharmaceuticals.
- Monthly visits2.7K
▲ 14.5% vs previous month
- Unique visitors1K
per month
- Global rank#6,727,386
among all websites
- Category rank#6,728
Health · Biotechnology and Pharmaceuticals
- Bounce rate41%
- Pages per visit1.7
- Average visit29 sec
- DevicesDesktop 36% · Mobile 64%
Latest news on Assertio
Complete news archive for Assertio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Assertio
10 companies that operate in the same segment as Assertio (Pain Management), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 | |
Therapeutics for migraine treatment are developed using nasal delivery. | 2016 | San Francisco, California, United States | USD 74.13 M | – | 24 | |
Pain treatment products are developed through reformulation technologies. | 2007 | Herzliya, Central District, Israel | USD 12 M | USD 17 K | 6 | |
Drug delivery systems for CNS disorders and pain are developed. | 2006 | Emeryville, California, United States | USD 149.06 M | – | – | |
Developer of neuromodulation platform measuring biomarkers for chronic neurological condition treatment | 2010 | Bloomington, Indiana, United States | USD 530 M | USD 91.65 M | – | |
Therapies for pain and addiction treatment are developed. | 1977 | Saint-cloud, France | USD 248.09 M | USD 167.87 M | – | |
Novel drug products for chronic pain treatment are developed. | 2007 | Blue Bell, Pennsylvania, United States | USD 12.96 M | – | 17 | |
Abuse-deterrent extended-release therapeutics for chronic pain are developed. | 2002 | Canton, Ohio, United States | USD 103 M | USD 780.57 M | 357 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Assertio
Assertio was founded in 1995 and raised its 1st funding round 3 years after it was founded.
Assertio is headquartered in Lake Forest, United States. It is registered at Lake Forest, California, United States.
Assertio has 58 employees.
Annual revenue of Assertio is $124.96M as on Dec 31, 2024.
Developer of drugs to treat pain and other neurological diseases. It offers Nucynta ER indicated for the management of pain associated with diabetic peripheral neuropathy (DPN), Gralise for the management of postherpetic neuralgia (PHN), Cambia for acute treatment of migraine attacks, Lazanda for the management of breakthrough pain in cancer patients; and Zipsor, liquid filled capsules for relief of mild to moderate acute pain. Its pipeline developing drugs include cebranopadol, analgesic for the treatment of moderate to severe chronic nociceptive and neuropathic pain.
Assertio's top competitors include Flexion Therapeutics, Cara Therapeutics and Trevena.
Assertio offers Pharmaceutical Products and Business Development Services.
Yes, Assertio is publicly traded on NASDAQ under the ticker symbol ASRT.
Assertio has made 2 acquisitions, including OTREXUP, and Spectrum Pharmaceuticals.
Assertio has 12 investors. Key investors include Zydus Life, Oxford Finance, HBM Healthcare Investments, Biovail, and Deerfield.
Assertio operates through Assertio Therapeutics, Inc.
Yes. Assertio was acquired by Zydus Life in May 2026.